Startups are taking advantage of the deep tech in various innovative and transformative ways to solve complex problems and create new markets.
Human health is a relevant topic in the current context, where we are witnessing different challenges that technology has not yet addressed, such as population aging, malnutrition and neurodegenerative diseases, to name a few. However, in the near future, they could have a solution thanks to new alternatives from biotechnology companies and startups.
This topic was the center of the discussion at the 42nd Annual JP Morgan Healthcare Conference, in San Francisco, United States, one of the most important events in the industry that connects sector leaders, emerging companies, technologies innovators, creators and members of the investment community.
As CEO and Managing Partner of The Ganesha Lab, participating in the parallel events that took place during the aforementioned meeting allowed me to hold around 30 meetings with representatives of the Deep Tech and draw important conclusions that can be a real meeting point for the development of startups in Latin America.
Health and financing, opportunities for startups
First, there is cautious optimism about access to capital by 2024, driven by mergers and acquisitions, which will provide fresh capital to reinvest in new companies and funds. But one must be attentive to signals such as interest rates and geopolitical challenges, which could affect this provision.
Artificial intelligence (AI) is recognized as the greatest facilitator for improvements in the health area, although more concrete results are required to clarify its role. AI is expected to revolutionize access to health through the combination of technological devices with support instruments for patient monitoring.
However, conversations about neurological diseases such as Alzheimer’s and dementia; oncologies, diabetes and obesity, are, without a doubt, where there is greater potential and urgency in the development of technologies, through which large companies will play an important role given that they are willing to up their ante against these startup innovations. worldwide.
The escalation with Deep Tech
In this context, the imminent need to be attentive to support and invest in the creativity and ideas arising from ventures focused on solutions for the sector is revealed, since new technologies will take center stage in the development of products that respond to the needs of the sector. future, allowing us to generate a global impact on the quality of life of millions of people, given the scope that this type of technology has, its intrinsic mission and its high scalability potential.
As a global accelerator for Latin American startups based on science and technology, our focus is to find new contact networks and partners, which are a contribution to the development and scaling of startups –Deep Tech. Through this vision and mission as The Ganesha Lab, being part of JP Morgan Week allowed us to strengthen our international presence and generate interest that, in the future, will allow us to offer greater support and accompaniment to our current portfolio and to the startups that are incorporated into new editions of our program.
This type of health-focused event demonstrates that collaboration is key when accelerating projects around the world, through connections between startups and investors and having strategic partners whose tools can turn a good idea into a reality.
Markus Schreyer Markus is a German executive and businessman with more than thirty years of experience in the industry and the international market. He is the founder of The Ganesha Lab, a biotech accelerator, which provides internationalization, expansion and financing services to new biotechnology companies in Latin America. He has led the selection and investment in over 25 early and seed stage biotech companies originating from 6 Latin American countries, including Mexico, 7 of which he launched from Latam to the US.